Adaptive Biotechnologies Reports Strong Preliminary 2025 Results, Projects Profitability by End of 2026
ADPT has more than doubled off its 52-week low of $5.975.
Summary
Adaptive Biotechnologies reported strong preliminary 2025 financial results with significant revenue and clonoSEQ volume growth, and expects to achieve positive adjusted EBITDA and free cash flow by the end of 2026.
Key Events · Earnings and Guidance · ADPT
-
Strong Preliminary 2025 Financial Performance
Reported preliminary total revenue of approximately $277 million for full year 2025, a 55% increase year-over-year, with Q4 revenue up 51% to $72 million.
-
Significant clonoSEQ Volume Growth
clonoSEQ test volumes increased 39% for the full year 2025 to approximately 105,600 tests, with Q4 volumes up 43% to 30,000 tests.
-
Path to Profitability in 2026
Management expects to achieve positive adjusted EBITDA and positive free cash flow for the entire company by the end of 2026, alongside over 30% clinical volume growth.
-
Healthy Cash Position
Ended 2025 with approximately $227 million in cash, cash equivalents, and marketable securities.
Analysis · ADPT · Life Sciences
Adaptive Biotechnologies announced robust preliminary financial results for the fourth quarter and full year 2025, demonstrating significant growth in total revenue and clonoSEQ test volumes. The company's Minimal Residual Disease (MRD) segment, driven by clonoSEQ adoption, showed strong momentum. Crucially, management provided an optimistic outlook for 2026, projecting over 30% clinical volume growth and, most notably, achieving positive adjusted EBITDA and free cash flow by the end of the year. This anticipated shift to profitability is a key milestone that could significantly de-risk the investment thesis and attract broader investor interest.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 35.6% of the 1100 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ADPT was trading at $18.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $5.98 to $20.76. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.